NCT03209492

Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 333 (actual)
• Sponsor: Takeda · Industry
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.

Detailed description

The drug being tested in this study is called Leuprorelin acetate (Leuplin PRO for Injection Kit 22.5 mg). Leuprorelin acetate is being tested to treat people who have prostate cancer. This study will look at the safety in patients with prostate cancer receiving the drug in the routine clinical setting. The study will enroll approximately 300 patients. • Leuprorelin acetate This multi-center trial will be conducted in Japan.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Leuprorelin acetate	Leuplin PRO for Injection Kit 22.5 mg

Timeline

• Start date: 2016-04-01
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2017-07-06
• Last updated: 2019-04-11
• Results posted: 2019-04-11

Locations

1 site across 1 country: Japan